NEXGEL, Inc. (NXGLW) Stock Price & Analysis

NEXGEL, Inc. (NXGLW) Healthcare & Pipeline Overview

NEXGEL, Inc. manufactures and sells high water content hydrogels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. Operating through its Nexgel and CG labs segments, the company offers over-the-counter solutions and develops advanced medical products like NEXDrape and NEXDerm, positioning itself in the broader healthcare and beauty markets.

What Is the Investment Thesis for NXGLW?

NEXGEL, Inc. presents a focused investment opportunity within the specialized hydrogel market, targeting wound care, medical diagnostics, and cosmetic applications. With a gross margin of 40.8%, the company demonstrates potential for profitability, although its current profit margin is -24.7% and ROE is -52.8%. Key to NEXGEL's growth is the successful development and commercialization of products like NEXDrape and NEXDerm, which address specific needs in the medical sector. The company's debt-to-equity ratio of 57.24 indicates a moderate level of leverage. A primary risk lies in achieving profitability and managing cash flow, given the current negative free cash flow of $-0.00B. The company's beta of 0.62 suggests lower volatility compared to the market. Successful penetration into the wound care and cosmetic markets, coupled with efficient management of resources, will be crucial for realizing shareholder value.

Based on FMP financials and quantitative analysis

NXGLW Key Highlights

Gross Margin of 40.8% indicates potential for profitability in hydrogel products.

• Debt-to-Equity Ratio of 57.24 suggests a moderate level of financial leverage.
• Developing NEXDrape and NEXDerm targets specific needs in the medical sector.
• Profit Margin of -24.7% indicates current challenges in achieving profitability.
• Free Cash Flow of $-0.00B highlights the need for improved cash management.

Who Are NXGLW's Competitors?

NXGLW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NXGLW's Key Strengths?

Specialized expertise in hydrogel technology.

• Proprietary electron beam cross-linking process.
• Diverse product applications across healthcare and cosmetics.
• Development of innovative medical products.

What Are NXGLW's Weaknesses?

Negative profit margin and ROE.

• Limited market presence compared to larger competitors.
• Dependence on successful commercialization of new products.
• Negative free cash flow.

What Are the Key Risks for NXGLW?

Financial-distress signal — its Altman Z-Score of -1.78 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve profitability and manage cash flow effectively.
• Competition from larger companies with greater resources and market share.
• Regulatory challenges in obtaining approvals for medical products.
• Dependence on successful commercialization of new products to drive revenue growth.

What Threats Does NXGLW Face?

• Competition from larger companies with greater resources.
• Regulatory hurdles for medical products.
• Fluctuations in raw material costs.
• Potential product liability claims.

What Are NXGLW's Competitive Advantages?

• Specialized expertise in high water content hydrogels.
• Proprietary electron beam cross-linking technology.
• Established brands in wound care and cosmetics.
• Development of innovative medical products like NEXDrape and NEXDerm.

What Does NXGLW Do?

NEXGEL, Inc., established in 2009 and based in Langhorne, Pennsylvania, specializes in the development, manufacturing, and sale of high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. These hydrogels are utilized across a diverse range of applications, including wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates through two primary segments: Nexgel and CG labs. Through these segments, NEXGEL offers a variety of over-the-counter remedy solutions, such as products for blister treatment and pain relief, as well as beauty and cosmetic solutions marketed under brands like Lumagel Beauty, Kenkoderm and Silly George. NEXGEL is also actively involved in the development of innovative medical products. These include NEXDrape, an incise surgical drape designed to protect patients with impaired skin during surgical procedures, and NEXDerm, an adhesive tape engineered to securely hold central lines, intravenous tubes, and other medical devices in place before, during, and after medical treatments. Furthermore, NEXGEL engages in converting and packaging services, providing comprehensive solutions for its clients. The company was formerly known as AquaMed Technologies, Inc., before rebranding to NEXGEL, Inc. in November 2019 to better reflect its focus on hydrogel technology. NEXGEL aims to leverage its expertise in hydrogels to address unmet needs in the healthcare and beauty industries.

What Products and Services Does NXGLW Offer?

• Manufactures high water content hydrogels.
• Utilizes electron beam cross-linking technology.
• Develops hydrogels for wound care applications.
• Creates hydrogels for medical diagnostics.
• Produces hydrogels for transdermal drug delivery.
• Offers hydrogels for cosmetic applications.
• Engages in converting and packaging services.

How Does NXGLW Make Money?

• Manufacturing and selling hydrogel-based products.
• Generating revenue through over-the-counter remedy solutions.
• Developing and commercializing advanced medical products.
• Providing converting and packaging services.

What Industry Does NXGLW Operate In?

NEXGEL, Inc. operates within the broader healthcare and cosmetics industries, focusing on hydrogel-based products. The market for advanced wound care and drug delivery systems is growing, driven by an aging population and increasing demand for innovative medical solutions. The cosmetics industry also presents opportunities for hydrogel-based products, particularly in skincare and beauty applications. Competition includes companies specializing in wound care, medical adhesives, and cosmetic ingredients. NEXGEL aims to differentiate itself through its high water content hydrogels and electron beam cross-linking technology.

Who Are NXGLW's Key Customers?

• Healthcare providers and hospitals.
• Cosmetic companies and retailers.
• Patients requiring wound care solutions.
• Consumers seeking beauty and cosmetic products.

NEXGEL, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 42.1% below estimates on average.

NEXGEL, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.78 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -23.4%, showing how much profit it generates from its asset base. A current ratio of 0.43 means current liabilities exceed short-term assets, a liquidity point worth watching.

NXGLW Revenue & Earnings Trend

In Q2 FY2026, NXGLW generated $3.7M in top-line revenue, marking a sequential increase of 39.1%. The company recorded a net loss of $3.6M, with diluted EPS of $-0.40. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Unknown. Across the four most recent quarters, NXGLW averaged $-0.18 in diluted EPS.

Company Profile

NEXGEL, Inc. operates in the Healthcare sector. It is headquartered in Langhorne, US. The company is led by CEO Brian J. Kieser. NXGLW has traded publicly since 2021.

NXGLW Financials

NXGLW Latest News

NXGLW Analyst Consensus

NXGLW MoonshotScore

Common Questions About NXGLW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources